768 related articles for article (PubMed ID: 18502181)
21. Effect of tandem forms of DAF(CD55) on complement-mediated xenogeneic cell lysis.
Miyagawa S; Fukuta D; Kitano E; Kobayashi C; Fumimoto Y; Shirasu A; Hattori H; Shirakura R; Fukuzawa M
Xenotransplantation; 2006 Sep; 13(5):433-9. PubMed ID: 16925667
[TBL] [Abstract][Full Text] [Related]
22. Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells.
Finberg RW; White W; Nicholson-Weller A
J Immunol; 1992 Sep; 149(6):2055-60. PubMed ID: 1381394
[TBL] [Abstract][Full Text] [Related]
23. A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation.
Peng W; Zhang X; Mohamed N; Inghirami G; Takeshita K; Pecora A; Nardone LL; Pincus SE; Casey LS; Spitalny GL
Cancer Immunol Immunother; 2005 Dec; 54(12):1172-9. PubMed ID: 15846490
[TBL] [Abstract][Full Text] [Related]
24. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.
Li B; Shi S; Qian W; Zhao L; Zhang D; Hou S; Zheng L; Dai J; Zhao J; Wang H; Guo Y
Cancer Res; 2008 Apr; 68(7):2400-8. PubMed ID: 18381448
[TBL] [Abstract][Full Text] [Related]
25. BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties.
Nishida M; Uematsu N; Kobayashi H; Matsunaga Y; Ishida S; Takata M; Niwa O; Padlan EA; Newman R
Int J Oncol; 2011 Feb; 38(2):335-44. PubMed ID: 21152859
[TBL] [Abstract][Full Text] [Related]
26. NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab.
Markasz L; Vanherberghen B; Flaberg E; Otvös R; Stuber G; Gustafsson Jernberg A; Olah E; Skribek H; Szekely L
Biomed Pharmacother; 2009 Jul; 63(6):413-20. PubMed ID: 18834693
[TBL] [Abstract][Full Text] [Related]
27. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
28. Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide.
Du J; Wang H; Zhong C; Peng B; Zhang M; Li B; Hou S; Guo Y; Ding J
Mol Immunol; 2008 May; 45(10):2861-8. PubMed ID: 18346788
[TBL] [Abstract][Full Text] [Related]
29. Human DAF on pig cells protects against human and non-human primate sera cytotoxicity mediated by exogenous or endogenous complement, as determined by flow cytometry.
Díaz-Román TM; Mañez R; López-Pelaez E; Centeno A; Moscoso I; Pértegaz S; Doménech N
Transpl Immunol; 2006 Aug; 16(2):125-30. PubMed ID: 16860716
[TBL] [Abstract][Full Text] [Related]
30. Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy.
Bjørge L; Stoiber H; Dierich MP; Meri S
Scand J Immunol; 2006 May; 63(5):355-64. PubMed ID: 16640659
[TBL] [Abstract][Full Text] [Related]
31. Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).
Klausz K; Berger S; Lammerts van Bueren JJ; Derer S; Lohse S; Dechant M; van de Winkel JG; Peipp M; Parren PW; Valerius T
Cancer Sci; 2011 Oct; 102(10):1761-8. PubMed ID: 21718386
[TBL] [Abstract][Full Text] [Related]
32. Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets.
Maloney DG
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S19-26. PubMed ID: 15786022
[TBL] [Abstract][Full Text] [Related]
33. A study of the xenoantigenicity of neonatal porcine islet-like cell clusters (NPCC) and the efficiency of adenovirus-mediated DAF (CD55) expression.
Omori T; Nishida T; Komoda H; Fumimoto Y; Ito T; Sawa Y; Gao C; Nakatsu S; Shirakura R; Miyagawa S
Xenotransplantation; 2006 Sep; 13(5):455-64. PubMed ID: 16925670
[TBL] [Abstract][Full Text] [Related]
34. Mimotope vaccination for epitope-specific induction of anti-CD20 antibodies.
Li M; Yan Z; Han W; Zhang Y
Cell Immunol; 2006 Feb; 239(2):136-43. PubMed ID: 16814270
[TBL] [Abstract][Full Text] [Related]
35. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.
Harjunpää A; Junnikkala S; Meri S
Scand J Immunol; 2000 Jun; 51(6):634-41. PubMed ID: 10849376
[TBL] [Abstract][Full Text] [Related]
36. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
Zhou X; Hu W; Qin X
Oncologist; 2008 Sep; 13(9):954-66. PubMed ID: 18779537
[TBL] [Abstract][Full Text] [Related]
37. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
Nishida M; Usuda S; Okabe M; Miyakoda H; Komatsu M; Hanaoka H; Teshigawara K; Niwa O
Int J Oncol; 2007 Jul; 31(1):29-40. PubMed ID: 17549402
[TBL] [Abstract][Full Text] [Related]
38. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.
Lefebvre ML; Krause SW; Salcedo M; Nardin A
J Immunother; 2006; 29(4):388-97. PubMed ID: 16799334
[TBL] [Abstract][Full Text] [Related]
39. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
Hu S; Zhu Z; Li L; Chang L; Li W; Cheng L; Teng M; Liu J
Proteins; 2008 Feb; 70(3):938-49. PubMed ID: 17847085
[TBL] [Abstract][Full Text] [Related]
40. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
Mishima Y; Sugimura N; Matsumoto-Mishima Y; Terui Y; Takeuchi K; Asai S; Ennishi D; Asai H; Yokoyama M; Kojima K; Hatake K
Clin Cancer Res; 2009 May; 15(10):3624-32. PubMed ID: 19417028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
